Karyopharm Therapeutics Inc. Share Price & Technical Analysis
KPTI · $8.16 (+1.24%)
Healthcare / Biotechnology
$8.16
+1.24%
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-2% return in May, -28% avg return in past 3 year May month.
39% return in 2026, -15% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -12% | 45% | -39% | 48% | -2% | – | – | – | – | – | – | – | 39% |
| 25 | -12% | -15% | -53% | 84% | -38% | 2% | -12% | 92% | -6% | -8% | -3% | 32% | 63% |
| 24 | -14% | 44% | 26% | -32% | -9% | -12% | 10% | -22% | 11% | 20% | -15% | -20% | -12% |
| 23 | -2% | -8% | 30% | -7% | -36% | -21% | 2% | -26% | 4% | -35% | -11% | 13% | -97% |
| 22 | 37% | 16% | -30% | -18% | 4% | -29% | -6% | 20% | 9% | -15% | 10% | -36% | -37% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Uptrend · Neutral
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$197.77M
P/E ratio
—
52W high
$10.99
52W low
$3.65
Volume
2,94,996
Beta
0.81
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Karyopharm Therapeutics Inc. share price today?
- Karyopharm Therapeutics Inc. (KPTI) last traded around $8.16 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does KPTI have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for KPTI. Download the app for real-time alerts.
- How can I analyze Karyopharm Therapeutics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.